查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1978237

2026-2034年全球慢性腎臟病（CKD）治療市場規模、佔有率、趨勢和成長分析報告

Global Chronic Kidney Disease (CKD) Drugs Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 116 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計慢性腎臟病(CKD) 治療市場規模將從 2025 年的 198.7 億美元成長到 2034 年的 294.8 億美元，2026 年至 2034 年的複合年成長率為 4.48%。

隨著全球腎臟疾病盛行率的上升，慢性腎臟病）治療的全球市場也在穩定成長。糖尿病和高血壓的增加以及人口老化等因素顯著促進了慢性腎臟病發生率的上升。由於CKD進展緩慢且需要長期管理，因此對有效藥物療法的需求日益成長。醫療機構正致力於早期診斷和治療，以延緩疾病進展並減少併發症。

製藥公司正大力投資研發，以推出腎臟功能及其相關併發症的新治療方法。諸如SGLT2抑制劑和鹽皮質激素受體拮抗劑等新型藥物在延緩慢性腎臟病（CKD）進展方面展現出令人鼓舞的療效。此外，聯合治療的日益普及也正在改善患者的預後。各國政府和醫療機構也在實施旨在提高公眾對CKD認知和改善治療可近性的計畫。

展望未來，生物技術和精準醫療的進步預計將為市場帶來顯著創新。針對新型腎臟病治療方法的臨床試驗數量增加，將拓寬治療選擇。此外，開發中國家醫療基礎設施的改善和腎臟病治療可近性的提高，預計也將促進市場的長期成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球慢性腎臟病（CKD）治療市場：依藥物類別分類

  • 市場分析、洞察與預測
  • ACE抑制劑
  • 血管收縮素II受體拮抗劑
  • 鈣離子通道阻斷劑
  • BETA阻斷劑
  • 促紅血球生成因子（ESA）
  • 利尿劑
  • 其他

第5章 全球慢性腎臟病（CKD）治療市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 醫院
  • 專科診所

第6章 全球慢性腎臟病（CKD）治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc
    • Sanofi
    • GSK Plc
    • Kissei Pharmaceutical Co. Ltd
    • AbbVie Inc
    • Akebia Therapeutics Inc
    • AstraZeneca
    • Amgen Inc
    • Teva Pharmaceutical Industries Ltd
簡介目錄
Product Code: VMR112114354

The Chronic Kidney Disease (CKD) Drugs Market size is expected to reach USD 29.48 Billion in 2034 from USD 19.87 Billion (2025) growing at a CAGR of 4.48% during 2026-2034.

The global chronic kidney disease drugs market is expanding steadily due to the rising prevalence of kidney disorders worldwide. Factors such as increasing rates of diabetes, hypertension, and aging populations are contributing significantly to the growing incidence of chronic kidney disease. As CKD progresses gradually and requires long-term management, the demand for effective pharmaceutical therapies is increasing. Healthcare providers are focusing on early diagnosis and treatment to slow disease progression and reduce complications.

Pharmaceutical companies are investing heavily in research and development to introduce novel therapies targeting kidney function and related complications. New classes of drugs, including SGLT2 inhibitors and mineralocorticoid receptor antagonists, are showing promising results in slowing CKD progression. Additionally, the growing availability of combination therapies is improving patient outcomes. Governments and healthcare organizations are also implementing programs aimed at improving CKD awareness and treatment accessibility.

Looking ahead, the market is expected to witness significant innovation as biotechnology and precision medicine approaches advance. Increasing clinical trials for new kidney disease therapies will likely expand the treatment landscape. Moreover, improving healthcare infrastructure and expanding access to nephrology treatments in developing countries will contribute to long-term market growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

  • ACE Inhibitors
  • Angiotensin-II Receptor Blockers
  • Calcium Channel Blockers
  • Beta Blockers
  • Erythropoiesis-stimulating Agents (ESAs)
  • Diuretics
  • Others

By End-user

  • Hospitals
  • Specialty Clinics

COMPANIES PROFILED

  • F HoffmannLa Roche Ltd, Pfizer Inc, Sanofi, GSK plc, Kissei Pharmaceutical Co Ltd, AbbVie Inc, Akebia Therapeutics Inc, AstraZeneca, Amgen Inc, Teva Pharmaceutical Industries Ltd
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL CHRONIC KIDNEY DISEASE (CKD) DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Class
  • 4.2. ACE Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Angiotensin-II Receptor Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Calcium Channel Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Beta Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Erythropoiesis-stimulating Agents (ESAs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Diuretics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CHRONIC KIDNEY DISEASE (CKD) DRUGS MARKET: BY END-USER 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast End-user
  • 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CHRONIC KIDNEY DISEASE (CKD) DRUGS MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Drug Class
    • 6.2.2 By End-user
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Drug Class
    • 6.3.2 By End-user
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Drug Class
    • 6.4.2 By End-user
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Drug Class
    • 6.5.2 By End-user
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Drug Class
    • 6.6.2 By End-user
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL CHRONIC KIDNEY DISEASE (CKD) DRUGS INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 F. Hoffmann-La Roche Ltd
    • 8.2.2 Pfizer Inc
    • 8.2.3 Sanofi
    • 8.2.4 GSK Plc
    • 8.2.5 Kissei Pharmaceutical Co. Ltd
    • 8.2.6 AbbVie Inc
    • 8.2.7 Akebia Therapeutics Inc
    • 8.2.8 AstraZeneca
    • 8.2.9 Amgen Inc
    • 8.2.10 Teva Pharmaceutical Industries Ltd